Pfizer (NYSE:PFE) Stock Falls 1.4% – Should You Sell?

Pfizer Inc. (NYSE:PFE) shares traded down 1.4% on Monday. The company traded as low as $27.12 and last traded at $27.4150. Approximately 32,348,021 shares changed hands during mid-day trading, a decline of 20% from the average session volume of 40,668,301 shares. The stock had previously closed at $27.80.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s turnaround case remains a potential support for the stock. The company has reportedly delivered ten consecutive earnings beats, while declining COVID-related headwinds and a possible obesity-drug pipeline deal could provide new growth and an estimated 20% upside. Pfizer’s Turnaround Could Be Bigger Than Investors Think
• Positive Sentiment: Pfizer’s roughly 6% dividend yield and diversified pharmaceutical portfolio continue to attract income-focused investors. Some analysts argue that the company’s restructuring and pipeline investments could support firmer growth beginning in 2029 despite upcoming patent expirations. Here’s Exactly Why I’m Not Afraid of Pfizer’s 6% Dividend Yield
• Neutral Sentiment: Leerink Partners maintained a “Hold” view on Pfizer, reflecting a balance between the stock’s relatively inexpensive valuation and high yield and concerns about growth, patents and execution. Pfizer Receives a Hold from Leerink Partners
• Negative Sentiment: Florida’s attorney general sued Pfizer and CEO Albert Bourla, alleging deceptive marketing of the company’s COVID-19 vaccine and failure to disclose health risks. The litigation creates potential legal costs, reputational damage and renewed scrutiny of Pfizer’s vaccine business. Florida Attorney General Sues Pfizer for Misleading COVID-19 Vaccine Safety Claims
• Negative Sentiment: Vaxcyte’s strong vaccine-study results have highlighted a potential competitive threat to Pfizer and Merck in a market estimated at $3 billion to $6 billion. The development could raise concerns about Pfizer’s long-term vaccine market share. Vaxcyte Stock Spikes as Lead Vaccine Candidate Takes Aim at Pfizer and Merck
• Negative Sentiment: Moderna’s rally ahead of full melanoma-vaccine data has made Pfizer look less attractive by comparison, particularly as investors favor competitors with promising next-generation oncology and mRNA platforms. Moderna Surges as Full Melanoma Readout Nears

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Bank of America lowered their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Monday, July 6th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target on the stock in a research note on Tuesday, June 9th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Finally, Guggenheim decreased their price objective on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $28.39.

Pfizer Price Performance

The firm has a market cap of $156.26 billion, a price-to-earnings ratio of 36.07, a PEG ratio of 1.87 and a beta of 0.32. The company’s fifty day moving average is $27.41 and its 200 day moving average is $26.48. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the previous year, the firm posted $0.78 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Keb Asset Management LLC acquired a new position in shares of Pfizer during the 2nd quarter worth about $26,000. Field & Main Bank acquired a new stake in Pfizer in the 2nd quarter valued at about $27,000. Evolution Wealth Management Inc. grew its holdings in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the period. Bullseye Investment Management LLC acquired a new position in Pfizer during the second quarter worth approximately $28,000. Finally, Timbuktu Capital Management LLC acquired a new stake in shares of Pfizer in the second quarter valued at approximately $29,000. 68.36% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.